This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

2022 Information Coming Soon!

Gestur Vidarsson, Ph.D.
Head of Immunoglobulin Research/PI, Experimental Immunohematology at Sanquin Research

Profile

Dr. Vidarsson is a principle investigator at the Department of Experimental Immunohematology, head of Immunoglobulin Research laboratory at Sanquin Research and a principal investigator of the Amsterdam University Medical Center, University of Amsterdam.  He holds a BSc in molecular biology and an MSc in Immunology from the University of Iceland, and obtained his doctorate from the Department of Immunology, University Medical Center Utrecht (UMCU) in 2000. He completed postdoctoral fellowships at UMCU’s Eijkman Graduate School for Immunology and Infectious Diseases; the Vaccine Research Laboratory at the Netherlands Vaccine Institute, Bilthoven; and the Department of Experimental Immunohematology, Sanquin Research and Landsteiner Laboratory.


Or work focuses on humoral Immune responses emphasizing on antibody biology in humans.  This includes work on Fc-receptors, complement and antibody glycosylation where study its significance in human immune responses. To do this we use antigen-specific IgG glycosylation analysis and glycoengineering, in conjunction single cell B cell techniques. We are also actively putting these tools for diagnostic purposes in antibody testing in pregnancy and for therapeutic purposes.


According to Google scholar, his work has been cited approximately 6300 times yielding a h-index of 40, with 73 papers cited more than 10 times in the last 5 years.  He received a European Community Biotechnology program grant enabling his own PhD project,  has among other intramural Sanquin grants, been awarded five times with grants from the “Landsteiner Stichting voor Bloedtransfusie Research” (LSBR) (>2 M€), was a co-applicant for an NWO Investment subsidy in 2012 (0.47 M€), co-applicant for as Dutch Cancer research grant (KWF 0.55 M€) and a lead applicant for a COVID-19 grant from the Duch ZonMW funding scheme (0.42 M€) . His work has led to several collaborations with biopharma and currently has one post doc and one PhD student financed through his connections with Genmab (Netherlands) and argenx (Belgium). He has supervised 11 PhD students successfully completing their defense, and is currently (co) supervising 6 PhD students), 3 technicians and two post docs.

Agenda Sessions

  • Sugar Switches of IgG in Human Immune Responses Affect the Outcome of COVID-19

    10:30